Supplementary Table S1-19 from Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations

Supplementary Table S1-19 from Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations

<p>Supplementary Table S1-19</p>

Saved in:

Bibliographic Details
Main Author:	Yuxi Liu (15293121) (author)
Other Authors:	Alexander Gusev (11666368) (author), Peter Kraft (12074932) (author)
Published:	2025
Subjects:	Cancer Cancer Biology Molecular and Cellular Biology Immuno-oncology Clinical Research and Trials Epidemiology Carcinogenesis Mutagenesis Gene Regulation Genetics of Cancer Risk & Outcome Immunotherapy Oncogenes & Tumor Suppressors Precision Medicine
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
by: Xufeng Lu (14960724)
Published: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
by: Renumathy Dhanasekaran (14962092)
Published: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
by: Francisco Exposito (16721403)
Published: (2025)

Supplementary Figure 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Figure 2 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Figure 3 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Figure 4 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Supplementary Table 1 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
by: Bo Yan (15062907)
Published: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
by: Diwakar Davar (15023480)
Published: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
by: Diwakar Davar (15023480)
Published: (2025)

Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Table 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Table 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
by: John Powderly (15026168)
Published: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
by: Xiaodong Shu (16721586)
Published: (2025)